ARG1 and gastric cancer: In addition, the dual arginase inhibitor OATD-02 restores intratumoral L-arginine levels by blocking arginase 1 (ARG1) and arginase 2 (ARG2)-mediated depletion, thereby reducing polyamine biosynthesisand enhancing antitumor immune responses with increased T-cell infiltration in tumors; this strategy may be used to enhance the efficacy of immunotherapy for gastric cancer and improve the antitumor outcomes [117].